Stock vs Stock Comparison

DexCom, Inc. vs Agilent Technologies, Inc.

DXCM wins the Tale of the Tape 5–4.

DXCM$72.77
A$137.40

🏆 Tale of the Tape

54
DXCMA
17.9%Profitability (Net Margin)18.8%
31.6xValuation (P/E)27.3x
20.8%Efficiency (ROIC)11.8%
6/9Health (Piotroski F)5/9
6.4Safety (Altman Z)4.6
15.6%Growth (Rev YoY)6.7%
-0.05Risk (Sharpe 1Y)0.32
1.31xBalance Sheet (D/E)0.89x
4.26%FCF Yield3.41%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.194
252-Day Correlation
0.222
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricDXCMA
Market Cap$28.5B$38.2B
P/E Ratio31.6x27.3x
Forward P/E24.0x20.5x
P/B9.62x5.37x
Dividend Yield0.75%
Beta1.401.22

Quantitative Metrics

MetricDXCMA
DCF Fair Value$56.48$50.34
DCF Upside-10.5%-57.1%
Piotroski F6/95/9
Altman Z6.384.57
Beneish M-2.69-2.46
FCF Yield4.26%3.41%
Net Debt/EBITDA0.2x0.7x
ROIC20.8%11.8%
WACC13.8%12.1%
ROIC – WACC7.0pp-0.3pp
Gross Margin60.1%52.4%
Net Margin17.9%18.8%
Rev Growth YoY15.6%6.7%
Sharpe (1Y)-0.050.32
Max Drawdown 3Y
FCF Payout Ratio24%

DXCM Price

Loading chart...

A Price

Loading chart...

ETF Exposure

DXCM found in:

XHE1.85%
VOT0.54%
XLV0.52%
VHT0.38%
VFQY0.33%
VO0.23%
RSP0.21%
QQQ0.14%
SCHG0.11%
IWF0.09%
VUG0.08%
VONG0.08%
ESGV0.05%
SPYV0.05%
SCHX0.05%
SPLG0.05%
IVV0.04%
SCHB0.04%
SPY0.04%
SPTM0.04%
SPYG0.04%
VOO0.04%
VONE0.04%
ITOT0.04%
ONEO0.04%
URTH0.03%
ACWI0.03%
VTI0.03%
QUS0.01%

A found in:

MOAT1.31%
VOT0.77%
XLV0.61%
VHT0.53%
VO0.33%
ONEV0.29%
RSP0.18%
VIG0.15%
VTV0.13%
SCHV0.12%
SPYV0.11%
IWD0.11%
VONV0.10%
ONEO0.09%
ESGV0.07%
QUS0.07%
SPLG0.07%
IVV0.07%
ITOT0.06%
SCHX0.06%
SCHB0.05%
SPY0.05%
VTI0.05%
VOO0.05%
VONE0.05%
SPTM0.05%
URTH0.04%
ACWI0.04%
DGRW0.04%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

DXCM vs A: Head-to-Head Analysis

DexCom, Inc. (DXCM) and Agilent Technologies, Inc. (A) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, DXCM leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, DXCM generates a return on invested capital (ROIC) of 20.8% compared to A's 11.8%. This suggests DXCM is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between DXCM and A is 0.194, indicating low correlation, making them an effective diversification pair in a portfolio context.

DXCM appears in 29 ETFs tracked by SecuritiesDB, while A appears in 29 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, DXCM or A?

Our quantitative analysis compares DXCM and A across nine fundamental dimensions. DXCM wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are DXCM and A correlated?

The 252-day correlation between DXCM and A is 0.194. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.